Welcome to our dedicated page for Quantum Cyber N.V. SEC filings (Ticker: MYNZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quantum Cyber N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quantum Cyber N.V.'s regulatory disclosures and financial reporting.
MAINZ BIOMED N.V. reported that Chief Executive Officer Guido Baechler acquired 440,000 Ordinary Shares on February 13, 2026 through a grant of restricted shares under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, with no cash consideration paid. Following this equity award, his directly held Ordinary Shares increased to 605,058. A footnote adds that 6,362 Ordinary Shares and 158,696 employee stock options had been granted earlier and were previously reported on a prior Form 3.
Mainz Biomed N.V. director Hans Hekland reported his existing equity interests with no buy or sell transactions. He directly holds 45,000 Ordinary Shares and several Employee Stock Options (Right to Buy), including positions with 10,000, 625, 250 and 125 underlying shares following the reported holdings.
One option grant vested 50% on 03/04/2025, with the remaining 25% tranches scheduled to vest on 03/24/2026 and 03/04/2027, while another option position is fully vested.
MAINZ BIOMED N.V. Schedule 13G/A amendment shows Armistice Capital, LLC and Steven Boyd reporting beneficial ownership of 435,128 ordinary shares, equal to 4.99% of the class. The filing is a joint statement amendment dated February 17, 2026.
The filing states Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., the direct holder of the shares, and that the Master Fund has the right to receive proceeds or dividends; the Master Fund disclaims beneficial ownership arising solely from the investment management agreement.
Mainz Biomed N.V. entered into a private placement with investor David Lazar for 6.0 USD million of convertible non-redeemable preferred stock, funded in two tranches of 3.0 USD million each. The first 3.0 USD million closed at 1.00 USD per preferred share; the second 3.0 USD million is expected after stockholder approvals at 1.50 USD per preferred share.
The preferred shares are highly dilutive: upon full conversion after required approvals, the First Closing Shares would represent about 55.4% and the Second Closing Shares about 90.2% of issued and outstanding ordinary shares on a fully diluted basis, or roughly 95.6% combined. Until conversion approval, a 19.99% beneficial ownership cap applies.
Net proceeds are earmarked for operations, working capital, and addressing liabilities. The company plans to focus on its U.S. pancreatic cancer detection program, explore sales of colorectal cancer screening assets, and wind down its German subsidiary. David Lazar was appointed Chair of the Board, and settlement agreements with certain officers and directors contemplate about 1.9 USD million of aggregate payments upon the final closing.
Mainz Biomed N.V. disclosed that it has completed share sales under a prospectus supplement tied to its equity distribution agreement with Maxim Group LLC. From January 5, 2026 through January 23, 2026, the company sold 1,735,194 ordinary shares on Nasdaq, generating aggregate gross proceeds of $2,152,822.40 before commissions and expenses.
The prospectus supplement allowed sales of ordinary shares up to an aggregate maximum offering price of $2,152,823, which has now been fully utilized. The broader equity distribution agreement, which permits offerings of up to $10,000,000 of ordinary shares, remains available for future sales, subject to market conditions and other factors.
Mainz Biomed N.V. Chief Financial Officer William J. Caragol filed an initial ownership report as of 01/01/2026. He reports beneficial ownership of 0 Ordinary Shares directly.
The filing lists several employee stock options to buy Ordinary Shares held directly. These include an option for 70,000 shares at an exercise price of $4.95, with 50% vested on 03/04/2025 and the remainder vesting 25% on 03/24/2026 and 25% on 03/04/2027. Additional options cover 3,899 shares at $200 (fully vested), 2,000 shares at $497.6, 1,000 shares at $302.8, and 1,000 shares at $191.2, each with four-year vesting schedules as described in the footnotes.
Mainz Biomed N.V. director Heiner Dreismann has filed an initial ownership report showing his current equity position in the company. The filing states that he directly holds employee stock options for 17,500 ordinary shares at an exercise price of $4.95, granted with 50% vesting upon grant on 03/04/2025 and the remaining 50% vesting in two 25% installments on 03/24/2026 and 03/04/2027. He also directly holds fully vested options for 250 ordinary shares at $302.8 and 1,950 ordinary shares at $200. The report shows 0 ordinary shares held directly, so his current economic exposure is through these option awards rather than owned shares.
Mainz Biomed N.V. director Gregory J. Tibbitts filed an initial Form 3 showing his beneficial holdings in the company’s securities as of 01/01/2026. He reports holding no ordinary shares directly, but does hold employee stock options over ordinary shares. One option grant covers 10,000 ordinary shares at an exercise price of $4.95, with 50% vested on 03/04/2025 and the remaining 25% tranches vesting on 03/24/2026 and 03/04/2027. He also holds fully vested options for 625 ordinary shares at $356.4 and 250 ordinary shares at $302.8, all owned directly.
Mainz Biomed N.V. filed an initial Form 3 showing Chief Executive Officer and director Guido Baechler’s beneficial ownership in the company’s securities as of 01/01/2026. He directly holds 6,362 ordinary shares.
Baechler also holds several employee stock options. One grant covers 145,000 ordinary shares at an exercise price of $4.95, with 50% vested on 03/04/2025 and the remaining 25% portions scheduled to vest on 03/24/2026 and 03/04/2027. A second grant for 11,696 ordinary shares at $200 per share is fully vested. A third grant for 2,000 ordinary shares at $302.8 per share vests over four years, with 25% vesting on 12/21/2023 and the remainder vesting monthly through 12/21/2026.
Mainz Biomed N.V. shareholder Kevin Donahue has filed an amended Schedule 13G reporting beneficial ownership of the company’s common stock. He reports holding 685,000 shares of Mainz Biomed common stock, representing 10.7% of the class, with the event triggering the filing dated 10/17/2025. Donahue has sole voting and sole dispositive power over all 685,000 shares, and no shared voting or shared dispositive power is reported. The filing is made in his capacity as an individual investor and indicates that he continues to own more than 5% of the company’s outstanding common stock.